ALFA Filings
Every announcement, straight from the exchange
Every Lupin business update announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements
Lupin Limited disclosed that the U.S. FDA concluded an inspection at its Goa manufacturing facility, closing with a Form-483 containing one observation. The company will respond within the stipulated timeframe.
Lupin received US FDA approval for its Diazepam Injection, USP, enabling its commercialization in the U.S. market.
Lupin Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance.
Lupin received an EIR from the U.S. FDA for its Somerset facility. The inspection resulted in a satisfactory VAI classification.